TriangleNCT02576990 · OUTCOME
Progression Free Survival (PFS) Based on IWG Response Assessment Criteria by Independent Central Review
Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.
- Measure
- MEDIAN
- Unit
- Months
- Interval / dispersion
- 95% Confidence Interval
- Time frame
- Up to approximately 27 months (Database Cutoff Date: 28MAY2019)
What was measured
PFS was defined as the time from first dose to the first documented progressive disease (PD) or death due to any cause, whichever occurs first. PD is the appearance of any new lesion or increase by ≥ 50% of previously involved site from nadir. Calculated from the product-limit (Kaplan-Meier) method for censored data.
Analysis population: The analysis population included all participants who received at least one dose of study medication (pembrolizumab).
Groups in this outcome
Pembrolizumab: Relapsed or Refractory Primary Mediastinal Large B-cell Lymphoma (rrPMBCL)
Pembrolizumab 200 mg every 3 weeks (Q3W), intravenous infusion (IV) on Day 1 of each 3-week cycle for up to 35 administrations (approximately 2 years).
Pembrolizumab: Relapsed or Refractory Richter Syndrome (rrRS)
Pembrolizumab 200 mg Q3W, IV on Day 1 of each 3-week cycle for up to 35 administrations (approximately 2 years).
| Group | Source count |
|---|---|
| Pembrolizumab: Relapsed or Refractory Primary Mediastinal Large B-cell Lymphoma (rrPMBCL) | 53 |
| Pembrolizumab: Relapsed or Refractory Richter Syndrome (rrRS) | 23 |
Reported measurements
Source class 1
| Group | Value | Spread | Lower | Upper | Comment |
|---|---|---|---|---|---|
| Pembrolizumab: Relapsed or Refractory Primary Mediastinal Large B-cell Lymphoma (rrPMBCL) | 5.5 | Not reported | 2.8 | 15.1 | Not reported |
| Pembrolizumab: Relapsed or Refractory Richter Syndrome (rrRS) | 1.6 | Not reported | 1.0 | 2.1 | Not reported |
Complete source fields
- classes
- categories
- measurements
- group Id
- OG000
- lower Limit
- 2.8
- upper Limit
- 15.1
- value
- 5.5
- group Id
- OG001
- lower Limit
- 1.0
- upper Limit
- 2.1
- value
- 1.6
- denoms
- counts
- group Id
- OG000
- value
- 53
- group Id
- OG001
- value
- 23
- units
- Participants
- description
- PFS was defined as the time from first dose to the first documented progressive disease (PD) or death due to any cause, whichever occurs first. PD is the appearance of any new lesion or increase by ≥ 50% of previously involved site from nadir. Calculated from the product-limit (Kaplan-Meier) method for censored data.
- dispersion Type
- 95% Confidence Interval
- groups
- description
- Pembrolizumab 200 mg every 3 weeks (Q3W), intravenous infusion (IV) on Day 1 of each 3-week cycle for up to 35 administrations (approximately 2 years).
- id
- OG000
- title
- Pembrolizumab: Relapsed or Refractory Primary Mediastinal Large B-cell Lymphoma (rrPMBCL)
- description
- Pembrolizumab 200 mg Q3W, IV on Day 1 of each 3-week cycle for up to 35 administrations (approximately 2 years).
- id
- OG001
- title
- Pembrolizumab: Relapsed or Refractory Richter Syndrome (rrRS)
- param Type
- MEDIAN
- population Description
- The analysis population included all participants who received at least one dose of study medication (pembrolizumab).
- reporting Status
- POSTED
- time Frame
- Up to approximately 27 months (Database Cutoff Date: 28MAY2019)
- title
- Progression Free Survival (PFS) Based on IWG Response Assessment Criteria by Independent Central Review
- type
- SECONDARY
- unit Of Measure
- Months
Download exact source JSON → · Snapshot ctgov-results-191f4516d4760045304b24a0
Preserved source evidence · Not medical advice